SNY Stock Recent News

- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 -

Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million.

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline

SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi (NASDAQ: SNY), an innovative global healthcare company, and Regeneron (NASDAQ: REGN), a leading biotechnology company, to deploy and evaluate an AI-powered workflow solution for chronic obstructive pulmonary disease (COPD). With support from Sanofi and Regeneron, Viz.ai will investigate the use of the Viz COPD module, a care a.

France's finance minister criticised on Thursday a decision by French drugmaker Sanofi to invest at least $20 billion in the United States through to 2030, as France aims to get more companies investing in the country rather than abroad.

French drugmaker Sanofi said on Wednesday it plans to invest at least $20 billion in the United States through 2030, which includes an increase in research and development spending and the allocation of billions of dollars to US manufacturing.

MORRISTOWN, N.J. and CAMBRIDGE, Mass.

Hawaii said on Friday it entered a $700 million settlement deal with pharmaceutical firm Bristol-Myers Squibb and units of French pharmaceutical company Sanofi in a case about warning labels related to health risks from blood thinner Plavix.

Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.

WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- As the Polish Presidency of the EU Council enters its final stage health policy remains central to Europe's strategic agenda. At the European Economic Congress in Katowice, discussions reflected both the Presidency's efforts to strengthen healthcare resilience and drive digital transformation, and a broader consensus that prevention, innovation, and life science leadership must be at the core of Europe's long-term strategy. Sanofi's experts highlighted the pivotal role of immunization, respiratory health, and sustainable innovation in building a healthier and competitive Europe.